// App-Quantinova.ai

10506.0 : Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results.

Researchers

Presenter

  • Birgit Geoerger

Principal Investigators

  • Eric Bouffet

  • James A. Whitlock

  • Christopher L. Moertel

  • Darren R. Hargrave

  • Isabelle Aerts

  • Kenneth J. Cohen

  • Lindsay Baker Kilburn

  • Karen D. Wright

  • Jeea Choi

  • Eduard Gasal

  • Mark W. Russo

  • Elizabeth Fox

Medical Centers

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

  • Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

  • University of Minnesota Masonic Childrens Hospital, Minneapolis, MN

  • Great Ormond Street Institute of Child Health, UCL, London, United Kingdom

  • Institut Curie, PSL Research University, Oncology Center SIREDO, Paris, France

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Children's National, Washington, DC

  • Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorder Center, Boston, MA

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Childrens Hospital of Philadelphia, Philadelphia, PA

Locations

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Mitogen-activated protein kinase

  • B-Raf proto-oncogene, serine/threonine kinase

Drug/Treatment

  • Dabrafenib Mesylate

  • Trametinib

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • NA

Study Id's

  • NCT02124772

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved